Anti-vascular endothelial growth factor for neovascular glaucoma

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 2, 2020, Pages

  Simha, Arathi ^a   Aziz, Kanza ^b   Braganza, Andrew ^a   Abraham, Lekha ^a   Samuel, Prasanna ^a   Lindsley, Kristina B ^c  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IBM WATSON HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BAY 86 5321; BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ENDOTHELIAL CELL GROWTH FACTOR; VASCULOTROPIN A;

CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; EYE REDNESS; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; LASER COAGULATION; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; REMISSION; RETINA DETACHMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ENDOTHELIAL GROWTH FACTORS; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85079047329     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007920.pub3     Document Type: Review

References (68)

1. ACTRN12607000577415. Efficacy and safety of intravitreal avastin in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82392 (first received 4 November 2007). x-wiley/crsRef/12753576
2. Arcieri ES, Paula JS, Jorge R, Barella KA, Arcieri RS, Secches DJ, et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmologica 2015;93(1):e1-6. x-wiley/crsRef/12753577
3. Arcieri ES, Secches DJL, Paula JS, Barella KA, Arcieri RS, Jorge R, et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation - preliminary report. ARVO. 2010:627/A471. x-wiley/crsRef/12753578
4. Jiang WP, Lu SS, Jin Y. Clinical research of retinal laser photocoagulation and ranibizumab on the treatment of neovascular glaucoma. International Eye Science 2015;15(10):1763-5. x-wiley/crsRef/12753580
5. Mahdy RA, Nada WM, Fawzy KM, Alnashar HY, Almosalamy SM. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. Journal of Glaucoma 2013;22(9):768-72. x-wiley/crsRef/12753582
6. NCT02396316. Japanese phase 3 study of aflibercept in neovascular glaucoma patients. clinicaltrials.gov/ct2/show/NCT02396316 (first received 24 March 2015). x-wiley/crsRef/12753584
7. Bodla AA, Bodla MA. A prospective study analyzing short term effects of intravitreal versus intracameral bevacizumab on neovascular glaucoma. Medical Forum Monthly 2017;28(4):9-12. x-wiley/crsRef/12753586
8. Caujolle JP, Maschi C, Freton A, Pages G, Gastaud P. Treatment of neovascular glaucoma after proton therapy for uveal melanomas with ranibizumab injection: preliminary results. Ophthalmic Research 2012;47(2):57-60. x-wiley/crsRef/2702478
9. Chakrabarti M, Chakrabarti A, Stephen V, John SR. Efficacy of combining intravitreal bevacizumab monotherapy with panretinal photocoagulation in early stages of neovascular glaucoma. American Academy of Ophthalmology. 2008:182. x-wiley/crsRef/12753588
10. ChiCTR-IPR-15006695. Adjunctive with intravitreal injection of ranibizumab before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a prospective randomized controlled study. www.chictr.org.cn/hvshowproject.aspx?id=11160 (first received 5 July 2015). x-wiley/crsRef/12753590
11. Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. British Journal of Clinical Pharmacology 2008;66(5):667-73. x-wiley/crsRef/2702480
12. Eid T, Radwan A, el-Manawy W, el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Canadian Journal of Ophthalmology 2009;44(4):451-6. x-wiley/crsRef/2702482
13. Eid TM, Radwan A, el-Menawy W, el-Hawary I. Outcome of intravitreal bevacizumab (Avastin) followed by aqueous shunting surgery for management of intractable neovascular glaucoma. American Academy of Ophthalmology. 2008:219. x-wiley/crsRef/2702483
14. EUCTR2007-000585-21-IE. Randomised controlled trial of intravitreal bevacizumab vs. conventional treatment for rubeotic glaucoma. www.clinicaltrialsregister.eu/ctr-search/trial/2007-000585-21/IE (first received 6 February 2007). x-wiley/crsRef/12753592
15. Georgalas I, Koutsandrea C, Papaconstantinou D, Petrou P, Ladas I. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2010;20(1):251. x-wiley/crsRef/2702485
16. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2009;19(3):435-41. x-wiley/crsRef/2702486
17. Jonas JB, Golubkina L, Libondi T, Rensch F. Intravitreal bevacizumab for neovascular glaucoma. Acta Opthalmologica 2010;88(2):e22-3. x-wiley/crsRef/2702488
18. Kong F, Ma X, Fan S, Lu J, Qin X, Zou J. Efficacy of intravitreal lucentis or conbercept injection combined with Ahmed glaucoma valve implantation for treatment of neovascular glaucoma. Journal of Jilin University (Medicine Edition) 2017;43(6):1237-42. x-wiley/crsRef/12753594
19. Lin N, Zheng WD, Li B. Clinical effect of ranibizumab combined with PPV on PDR with neovascular glaucoma at early stage. International Eye Science 2018;18(2):294-7. x-wiley/crsRef/12753596
20. Miki A, Oshima Y, Otori Y, Matsushita K, Nishida K. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy. Eye 2011;25(5):658-9. x-wiley/crsRef/2702490
21. NCT01128699. Ahmed valve glaucoma implant with adjunctive subconjunctival bevacizumab in refractory glaucoma. clinicaltrials.gov/ct2/show/NCT01128699 (first received 24 May 2010). x-wiley/crsRef/12753597
22. NCT01711879. Use of intravitreal aflibercept injection for neovascular glaucoma. clinicaltrials.gov/ct2/show/NCT01711879 (first received 22 October 2012). x-wiley/crsRef/2702492
23. NCT03154892. The effect of conbercept injection through different routes for neovascular glaucoma. clinicaltrials.gov/ct2/show/NCT03154892 (first received 16 May 2017). x-wiley/crsRef/12753599
24. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clinical Ophthalmology 2011;5(1):797-800. x-wiley/crsRef/2702494
25. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmologica Scandinavica 2006;84(4):556-7. x-wiley/crsRef/12753601
26. Wang F, Wang LL. Safety of anti-VEGF drugs with trabeculectomy for neovascular glaucoma. International Eye Science 2016;16(5):837-40. x-wiley/crsRef/12753603
27. Wittstrom E, Holmberg H, Hvarfner C, Andreasson S. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. European Journal of Ophthalmology 2012;22(4):563-74. x-wiley/crsRef/2702496
28. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. Journal of Glaucoma 2009;18(8):632-7. x-wiley/crsRef/12753605
29. NCT02914626. Intravitreal ranibizumab (Lucentis®) for neovascular glaucoma - a randomized controlled study. clinicaltrials.gov/ct2/show/NCT02914626 (first received 26 September 2016). x-wiley/crsRef/12753607
30. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 1994;331(22):1480-7.
31. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Current Opinion in Ophthalmology 2007;18(6):502-8. [PUBMED: 18163003]
32. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26(3):352-4.
33. Blankenship GW. A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1988;95(2):170-7.
34. Veritas Health Innovation. Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 1 May 2019.
35. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Delgado MF, Dickens CJ, Iwach AG, Novack GD, Nychka DS, Wong PC, et al. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology 2003;110(5):895-9.
37. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1984;91(12):1453-7.
38. Dong Z, Gong J, Liao R, Xu S. Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: a PRISMA-compliant network meta-analysis. Medicine 2018;97(14):e9897. [PUBMED: 29620670]
39. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28(5):696-702.
40. Gandhi JS. Use of antivascular agents for neovascular glaucoma: benefits beyond pressure?. Clinical and Experimental Ophthalmology 2008;36(1):102-3.
41. McMaster University (developed by Evidence prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence prime), accessed 2 January 2019.
42. Grover S, Gupta S, Sharma R, Brar VS, Chalam KV. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. British Journal of Ophthalmology 2009; Vol. 93, issue 2:273-4.
43. Ha JY, Lee TH, Sung MS, Park SW. Efficacy and safety of intracameral bevacizumab for treatment of neovascular glaucoma. Korean Journal of Ophthalmology 2017;31(6):538-47.
44. Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica 2003;217(3):167-88.
45. Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
46. Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
47. Hwang HB, Han JW, Yim HB, Lee NY. Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. Journal of Ocular Pharmacology and Therapeutics 2015;31(4):198-203. [PUBMED: 25714761]
48. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. American Journal of Ophthalmology 2006;142(6):1054-6.
49. Kang JY, Nam KY, Lee SJ, Lee SU. The effect of intravitreal bevacizumab injection before Ahmed valve implantation in patients with neovascular glaucoma. International Ophthalmology 2014;34(4):793-9.
50. Kiuchi Y, Nakae K, Saito Y, Ito S, Ito N. Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244(12):1627-32.
51. Kovacic Z, Ivanisevic M, Rogosic V, Plavec A, Karelovic D. Cyclocryocoagulation in treatment of neovascular glaucoma [Ciklokriokoagulacija u lijecenju neovaskularnoga glaukoma]. Lijecnicki Vjesnik 2004;126(9-10):240-2.
52. Minckler D, Vedula SS, Li T, Mathew M, Ayyala R, Francis B. Aqueous shunts for glaucoma. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004918.pub2]
53. Noor NA, Mustafa S, Artini W. Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience. Clinical Ophthalmology 2017;11:1417-22.
54. Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye 2016;30(3):463-72.
55. Pagenstecher H. Contribution to the teachings of hemorrhagic glaucoma [Beitrage zur Lehre vom hämorrhagischen Glaucom]. Graefe's Archive for Clinical and Experimental Ophthalmology 1871;17:98-130.
56. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
57. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2019, Issue 3. [DOI: 10.1002/14651858.CD005139.pub4]
58. Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 1996;19(11):1306-7.
59. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105(2):232-7.
60. Tsai JC, Wand M. Chapter 213: Neovascular Glaucoma. In: Alm A, Grosskreutz C editor(s). Albert and Jakobiec's Principles and Practice of Ophthalmology. 3rd Edition. Vol. 2, Canada: Saunders Elsevier, 2008:2689.
61. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115(9):1571-80.
62. Wilkins M, Indar A, Wormald R. Intraoperative mitomycin C for glaucoma surgery. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD002897.pub2]
63. Wormald R, Wilkins M, Bunce C. Postoperative 5-Fluorouracil for glaucoma surgery. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD001132]
64. Yalvac IS, Eksioglu U, Satana B, Duman S. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye 2007;21(1):65-70.
65. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. Journal of Glaucoma 2007;16(5):437-9.
66. Zhou M, Xu X, Zhang X, Sun X. Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. Journal of Glaucoma 2016;25(7):551-7. [PUBMED: 25719237]
67. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007920]
68. Simha A, Braganza A, Abraham L, Samuel P, Lindsley K. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD007920.pub2]